Document Detail


Use of a non-depleting anti-CD4 antibody to modulate the immune response to coagulation factors VIII and IX.
MedLine Citation:
PMID:  12181056     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The generation of antibodies to therapeutic factors VIII or IX is a major problem in the management of haemophilia and places potential limitations on the application of gene therapy. We have investigated the administration of a non-depleting anti-CD4 antibody for modulation of the immune response to human recombinant coagulation factors VIII and IX. In mice given these clotting factors, co-administration of anti-CD4 antibody significantly reduced the appearance of factor-specific antibodies. These data provide evidence that the neutralizing antibody response to exogenous coagulation factors may be controllable if non-depleting anti-CD4 antibody is co-administered at the time of initial replacement therapy.
Authors:
Nina Salooja; Geoffrey Kemball-Cook; Edward G D Tuddenham; Julian Dyson
Related Documents :
16988546 - The tissue factor pathway in ischemic stroke.
6186656 - Immunochemical characterization of klebsiella antigens which specifically modify an hla...
2147176 - Glomerular cr1 express in situ cofactor activity for degradation of c3b.
21822056 - Infections associated with monoclonal antibody and fusion protein therapy in humans.
8163416 - Cutaneous t-cell lymphoma in a cat.
2434696 - Antigenic similarity of onchocerca volvulus to other helminths examined by monoclonal a...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  British journal of haematology     Volume:  118     ISSN:  0007-1048     ISO Abbreviation:  Br. J. Haematol.     Publication Date:  2002 Sep 
Date Detail:
Created Date:  2002-08-15     Completed Date:  2002-11-06     Revised Date:  2003-11-14    
Medline Journal Info:
Nlm Unique ID:  0372544     Medline TA:  Br J Haematol     Country:  England    
Other Details:
Languages:  eng     Pagination:  839-42     Citation Subset:  IM    
Affiliation:
Haemostasis Research, MRC Clinical Sciences Centre, Imperial College School of Medicine, Hammersmith Hospital, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antibodies, Monoclonal / immunology
Antigens, CD4 / immunology*
Autoantibodies / biosynthesis
Factor IX / immunology*
Factor VIII / immunology*
Female
Immune Tolerance*
Lymphocyte Depletion
Mice
Mice, Inbred CBA
Recombinant Proteins / immunology
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antigens, CD4; 0/Autoantibodies; 0/Recombinant Proteins; 9001-27-8/Factor VIII; 9001-28-9/Factor IX

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  High P-glycoprotein-mediated export observed in patients with a history of idiopathic thrombocytopen...
Next Document:  The effect of plasma caeruloplasmin levels on the sensitivity for activated protein C.